OncLive TV

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Jubilee Brown, MD, discusses the utility of PARP inhibitors in patients with recurrent platinum-sensitive ovarian cancer.

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

George Simon, MD, FACP, FCCP, discusses the importance of next-generation sequencing in patients with non–small cell lung cancer.

Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.

Geoffrey Y. Ku, MD, discusses the rationale to evaluate zanidatamab in combination with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma.

Danny Nguyen, MD, discusses management strategies for mobocertinib-related gastrointestinal toxicities in EGFR exon 20 insertion–positive non–small cell lung cancer.

Maria Carmela Piccirillo, MD, discusses the safety profile of bevacizumab plus erlotinib in EGFR-mutated advanced nonsquamous non–small cell lung cancer.

Julio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.

Miranda Gogishvili, MD, discusses the rationale for the phase 3 EMPOWER-Lung 3 trial in advanced or metastatic non–small cell lung cancer.

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

Dipenkumar Modi, MD, discusses the utility of BTK inhibitors in chronic lymphocytic leukemia.

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Rachna T. Shroff, MD, MS, discusses unmet needs in advanced biliary tract cancer.

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.

Julie K. Heimbach, MD, discusses the need for multidisciplinary care in patients with hepatocellular carcinoma.

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Tadeusz Robak, MD, PhD, discusses the inclusion criteria of the the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

John L. Marshall, MD, discusses the results of the phase 2 DESTINY-Gastric02 trial in HER2-positive gastric and gastroesophageal junction cancers.

Syed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Timothy F. Burns, MD, PhD, discusses the promise of combination regimens for patients with EGFR exon 20 insertion– and KRAS G12C–mutated non–small cell lung cancer.

Liza C. Villaruz, MD, discusses selecting between single-agent and combination immunotherapy in non–small cell lung cancer.

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.